Can you run TRT without side effects? Here's what the data says

What did @gachau_njoroge actually say?

The creator ran through four TRT side effects and offered mitigation strategies for each. They claimed TRT causes "loss of fatigue" (almost certainly meant fertility), said small doses "can hardly make you lose your ability to reproduce," and suggested hCG and clomiphene can "revise the fatality issue." They also flagged hair loss, prostate enlargement (BPH), and elevated red blood cell count as risks, pairing each with a proposed fix: finasteride or RU-58841 for hair, 5-alpha reductase inhibitors for prostate, and blood donation or baby aspirin for red cell excess.

The format is ambitious. Four risks in under two minutes is a lot of ground to cover, and the compression shows. Some of what they said lands reasonably close to the evidence. Some of it is garbled in ways that could genuinely mislead someone making real health decisions.

Does the science back this up?

Partially, and the parts that don't check out are the ones that matter most. The fertility claim is the most problematic. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, reducing LH and FSH, which causes testicular atrophy and dramatically reduces sperm production. This is not a rare edge case. Contraceptive testosterone trials have exploited exactly this mechanism. Saying TRT "can hardly make you lose your ability to reproduce" at standard doses is flatly wrong.

The prostate claim is more nuanced. Older assumptions about TRT driving BPH and prostate cancer have largely been revised. Kacker et al. (2012, Journal of Sexual Medicine) and the testosterone trial consortium data suggest that, in men with documented hypogonadism, TRT does not significantly worsen lower urinary tract symptoms or dramatically increase prostate volume at physiologic doses. The BPH framing in this video overstates the current evidence for harm.

The polycythemia point is legitimate. TRT does increase erythropoiesis. Hematocrit elevation is one of the most consistently documented TRT side effects (Bachman et al., 2010, Journal of Clinical Endocrinology and Metabolism). Blood donation as a mitigation strategy has real-world use, though it isn't formally guideline-endorsed as a first-line response.

What did they get wrong (or right)?

Let's be direct. The fertility claim is the biggest error here. The creator said small TRT doses "can hardly" impair reproduction. That is not supported. Testosterone-induced suppression of spermatogenesis is well-documented even at replacement doses. Hamada et al. (2013, Asian Journal of Andrology) and the WHO contraceptive testosterone studies confirm sperm suppression is common, not incidental. hCG can preserve intratesticular testosterone and partially protect fertility, but framing it as a fix for a minor risk undersells how real the suppression is.

The hair loss section is mostly reasonable. Androgenetic alopecia in genetically susceptible men can be accelerated by TRT via DHT conversion. Finasteride blocks 5-alpha reductase and has evidence behind it for this purpose (Kaufman et al., 1998, Journal of the American Academy of Dermatology). RU-58841 is a topical androgen receptor antagonist with some preclinical and small human data, but it is not approved anywhere and recommending it without that caveat is a gap.

The prostate section is actually where the creator does better than expected, even if they overstate the risk. 5-alpha reductase inhibitors like dutasteride do reduce prostate volume. The clinical picture on TRT and prostate is more reassuring than older guidelines suggested, so the alarm is somewhat dated, but the mitigation mentioned is at least pharmacologically coherent.

What should you actually know?

TRT has real, manageable side effects, but the risk profile is more specific than this video conveys. Fertility suppression is not a minor footnote at standard doses. It is a predictable pharmacological consequence of exogenous androgen use that anyone of reproductive age needs to understand before starting. If preserving fertility matters, hCG co-administration or alternative approaches like clomiphene monotherapy are legitimate conversations to have with a physician, not afterthoughts.

Polycythemia is real and worth monitoring. Hematocrit should be checked regularly on TRT. The aspirin suggestion for blood thinning is not a standard clinical recommendation for this indication and should not replace proper hematologic monitoring.

The prostate cancer risk from TRT, in men without pre-existing disease, is not as firmly established as older guidelines implied. The Endocrine Society's 2018 clinical practice guidelines reflect this shift. That said, PSA monitoring remains standard practice.

Anyone considering TRT should be working with a licensed clinician who can order baseline labs, monitor hematocrit, PSA, and lipids, and adjust protocols based on actual bloodwork, not a two-minute TikTok.